Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 6, 2019updated 23 Dec 2019 9:32am

BMS’ CheckMate -548 trial fails to meet one primary endpoint

Bristol-Myers Squibb (BMS) has reported that the Phase III CheckMate -548 clinical study of an Opdivo (nivolumab) combination in glioblastoma multiforme (GBM) patients has failed to meet the primary endpoint of progression-free survival (PFS).

Bristol-Myers Squibb (BMS) has reported that the Phase III CheckMate -548 clinical study of an Opdivo (nivolumab) combination in glioblastoma multiforme (GBM) patients has failed to meet the primary endpoint of progression-free survival (PFS).

Opdivo is an immune checkpoint inhibitor of programmed death-1 (PD-1). It uses the body’s immune system to restore immune response against cancer.

The CheckMate -548 trial assessed the combination of Opdivo plus current standard of care comprising temozolomide and radiation therapy compared to standard of care alone.

Newly diagnosed patients with O6-methylguanine-DNA methyltransferase (MGMT)-methylated GBM have been enrolled into the randomised, multi-centre trial.

The trial’s primary endpoints are PFS and overall survival (OS), while secondary endpoints include investigator-assessed PFS and OS up to two years.

“We are continuing to evaluate the benefit of the addition of Opdivo to the standard of care treatment regimen may bring to patients suffering from GBM.”

After the study failed to meet the PFS primary endpoint, the data monitoring committee suggested that it can continue to allow the OS data to mature.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Bristol-Myers Squibb Oncology Development head Fouad Namouni said: “Though CheckMate -548 did not show statistically significant improvement in progression-free survival, we are continuing to evaluate the benefit of the addition of Opdivo to the standard of care treatment regimen may bring to patients suffering from GBM, an extremely aggressive and difficult disease to treat.

“We look forward to seeing the overall survival data when they are available.”

In June, the company announced that Opdivo did not meet the primary endpoint of overall survival in the Phase III CheckMate -459 study, compared to sorafenib, in unresectable hepatocellular carcinoma (HCC) patients.

BMS is developing Opdivo as a monotherapy and combination treatment for a wide range of cancers.

The drug already holds multiple approvals, including for the treatment of metastatic melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and small cell lung cancer (SCLC).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU